AIS curves generally progress during the adolescent period and slow by the time the patient reaches skeletal maturity. Credit: Scoliosis Treatment Crass Cheneau.

ApiFix has received US Food and Drug Administration (FDA) approval through a Humanitarian Device Exemption (HDE) to commercialise its Minimally Invasive Deformity Correction (MID-C) system to treat progressive adolescent idiopathic scoliosis (AIS).

AIS is a form of scoliosis that occurs in children of ages ten to 21. AIS curves generally progress during the adolescent period and slow by the time the patient reaches skeletal maturity.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

In cases where curve progression is more than 50˚, scoliosis can advance even at adulthood.

ApiFix CEO Paul Mraz said: “FDA approval of ApiFix’s MID-C system is a significant achievement for our company. More importantly, it makes notable treatment advancement available for patients and their families who want FDA approved alternatives to permanent spinal fusion.

“Our MID-C System addresses a significant unmet clinical need for a motion-preserving alternative to spinal fusion and is a viable treatment option for progressive scoliosis in a select group of AIS patients.”

The technology is a posterior dynamic deformity correction (PDDC) system that provides permanent curve correction and also retains the flexibility of the spine.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The MID-C is an internal brace equipped with a unidirectional, self-adjusting rod mechanism and motion-preserving polyaxial joints that can allow additional corrections over time.

ApiFix co-founder and chief medical officer Yizhar Floman said: “The FDA rigorously evaluated data from patients treated with ApiFix’s MID-C system since 2012 to demonstrate the safety and probable clinical benefits of our less invasive, non-fusion deformity correction system.”

The MID-C system has secured FDA and CE Mark approvals and is currently available in the US, Canada, Europe, Israel and Singapore.